Verona Pharma PLC Overview
Verona Pharma was a single-asset respiratory specialty pharmaceutical company that converted a four-decade-old molecule into one of the most successful commercial launches in modern respiratory medicine, and then monetised it. Its entire enterprise rested on ensifentrine — a first-in-class, inhaled, selective dual inhibitor of phosphodiesterase 3 and 4, marketed as Ohtuvayre — approved by the FDA on 26 June 2024 as the first novel inhaled mechanism for COPD maintenance treatment in more than twenty years. The Company self-commercialised in the United States through a roughly 120-representative field force and an exclusive specialty-pharmacy network, while out-licensing Greater China to Nuance Pharma. Quarterly net product sales rose from USD 5.6 million at launch to USD 102.9 million within four quarters, delivering the Company's first quarterly net income in Q2 2025. Fourteen months after approval, Merck acquired the business for approximately USD 10 billion — a valuation implying peak sales expectations of roughly USD 3–5 billion.
The Company's own characterisation
The Company described itself consistently across its final filings as "a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs" (FY2024 Form 10-K, Item 1; Q2 2025 Form 10-Q, Item 2). Its 10-K described Ohtuvayre as "our first commercial product and the first inhaled therapy with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years" and stated the Company's belief that Ohtuvayre "will redefine the treatment paradigm for COPD."
Independent characterisation
Verona Pharma was, in structural terms, a single-molecule, single-market, asset-light commercial pharmaceutical company. Four features defined the model:
A single asset with multi-indication optionality. Every dollar of enterprise value derived from ensifentrine. The Company acknowledged this explicitly as its foremost risk factor: "We depend solely on the success of ensifentrine" (FY2024 Form 10-K, Summary Risk Factors). The molecule's optionality lay in three vectors — additional indications (non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma), additional formulations (dry powder inhaler, pressurised metered-dose inhaler), and fixed-dose combinations (ensifentrine plus glycopyrrolate).
Asset-light manufacturing. The Company owned no manufacturing facilities. It relied on a single contract manufacturing organisation (CMO) for ensifentrine drug substance and one CMO for each formulation of drug product (FY2024 Form 10-K, "Manufacturing"). This maximised return on invested capital but concentrated supply-chain risk to a degree unusual even for specialty pharma.
Direct US commercialisation, partnered ex-US. In the United States the Company sold directly. Outside the United States, the stated strategy was to "license Ohtuvayre to companies with expertise and experience in developing and commercializing products in those regions." Only one such licence was ever executed — Nuance Pharma for Greater China (June 2021).
Medical-benefit reimbursement, specialty-pharmacy distribution. Ohtuvayre is a nebulised inhalation suspension administered through durable medical equipment, and was reimbursed under the medical benefit rather than the pharmacy benefit — reflected in its permanent product-specific HCPCS J-code (J7601), effective 1 January 2025. Product moved through an exclusive network of five accredited specialty pharmacies (Q2 2025 Form 10-Q, "Concentration of risk").
Revenue model and mix
| Revenue stream | Description | Materiality |
|---|---|---|
| US product sales (Ohtuvayre) | Net of distribution fees, government rebates and chargebacks, commercial chargebacks, returns, co-pay assistance and other fees | 100% of FY2024 revenue; 97.1% of H1 2025 revenue |
| Licensing / milestone income | Nuance Pharma collaboration: USD 40.0m upfront (2021), up to USD 179.0m in clinical, regulatory and commercial milestones, tiered double-digit royalties on Greater China net sales | 100% of FY2021 revenue; 2.9% of H1 2025 revenue |
| Clinical supply sales | Sale of clinical supply materials to Nuance Pharma | USD 0.458m in FY2022 only |
| Subscription / service revenue | — | Nil in all periods |
Value-chain position, customers and end-markets
Verona occupied the discovery-adjacent-to-commercial band of the value chain: it did not discover ensifentrine (the compound, originally RPL554, was assigned to it via the 2005 Rhinopharma/Vernalis agreement, and traces to the GSK respiratory research programme led by Sir David Jack), and it did not manufacture. It owned clinical development, regulatory strategy, intellectual property, brand, pricing and US commercial execution.
Its economic customers were the five specialty pharmacies that purchased product; its clinical customers were approximately 14,500 targeted US healthcare professionals — pulmonologists, internal-medicine physicians, primary-care physicians, nurse practitioners and physician assistants (FY2024 Form 10-K, "Commercialization"). Its ultimate payers were Medicare Part B, Medicare Advantage and commercial medical-benefit plans.
End-markets served: COPD maintenance treatment (United States, commercial); COPD (Greater China, partnered, approved in Macau); and, in development, non-cystic fibrosis bronchiectasis, cystic fibrosis and asthma.
Financial Narrative
All figures in USD millions unless stated. Basis: US GAAP as presented in the Company's SEC filings and quarterly consolidated financial summaries. FY2020 and FY2021 figures are drawn from the comparative table in the FY2021 results release of 3 March 2022; FY2022 and FY2021 from the FY2022 results release of 7 March 2023; FY2023 and FY2024 from the FY2024 results release and Form 10-K of 27 February 2025. Note that the Company's UK statutory accounts were prepared under IFRS and are not directly comparable line-by-line to the US GAAP presentation below.
Income statement, FY2020–FY2024
EBITDA is approximated as operating loss plus depreciation; depreciation was immaterial (USD 0.533m in H1 2024 and USD 0.588m in H1 2025 per the Q2 2025 Form 10-Q). There was no amortisation of intangibles, as the Company carried no amortisable intangible assets. Loss per ADS is derived by the analyst at the 8:1 ratio and is not a line item in the Company's filings.
Margin analysis
FY2023 percentages are shown as 0 because revenue was nil, rendering revenue-based margins undefined; the underlying operating loss was USD 67.569m. FY2022 margins are shown for completeness but are meaningless given a USD 0.458m revenue base.
Balance sheet, FY2020–FY2024 and H1 2025
Cash, total assets and equity for FY2020–FY2022 are taken from the comparative summaries in the FY2021 and FY2022 results releases; FY2023–FY2024 from the FY2024 Form 10-K balance sheet. Total liabilities for FY2020–FY2022 are derived by the analyst. Goodwill of USD 0.545m is the residual from the 2006 Rhinopharma acquisition and was unchanged in every period reviewed. The Company carried no amortisable intangible assets — the entire ensifentrine patent estate was expensed as incurred, which is why Merck had to capitalise almost the whole purchase price as a new intangible on acquisition.
Balance sheet detail, FY2023 / FY2024 / H1 2025: notes and sources
Sources: FY2024 Form 10-K consolidated balance sheets; Q2 2025 Form 10-Q condensed consolidated balance sheets. Net cash is derived as cash less total interest-bearing obligations (term loan plus RIPSA carrying values).
Cash flow
Source: Q2 2025 Form 10-Q, Condensed Consolidated Statements of Cash Flows. Dividends paid: nil in all periods. Share buybacks: nil in all periods.
Cash flow commentary. The single most important financial inflection in the Company's history occurred in Q2 2025, when operating cash flow turned positive for the first time. H1 2025 delivered USD 19.0 million of operating cash inflow against a USD 30.7 million outflow in H1 2024 — a USD 49.7 million swing driven entirely by Ohtuvayre receipts, partially offset by a USD 51.4 million build in accounts receivable as the specialty-pharmacy channel scaled. Capital expenditure was structurally negligible (USD 0.5 million in H1 2025) — the natural consequence of an asset-light, fully outsourced manufacturing model. Financing activity in H1 2025 was essentially a refinancing exercise: USD 122.5 million drawn on the upsized Tranche C offset by USD 109.9 million to retire the RIPSA, netting USD 12.6 million of new money plus USD 10.1 million from option exercises.
Ratio analysis
Notes: return metrics use end-period balances rather than averages to permit a complete five-year series; using two-point averages, FY2024 ROE would be -76.4% and ROA -44.3%. Interest coverage is shown as 0 where EBIT was negative and the ratio is not meaningful; the H1 2025 figure of 0.18x rises to 1.95x on a Q2 2025-only basis (USD 13.305m operating income over USD 6.822m interest expense). Asset turnover for H1 2025 is annualised revenue over end-period assets.
Cash conversion cycle. In FY2024 the cycle is not meaningful: the Company sold for only five months of the year and inventory metrics are distorted because pre-approval inventory was expensed to R&D rather than capitalised. On H1 2025 data — 181 days, revenue USD 174.195m, cost of sales USD 8.163m — days sales outstanding was approximately 86 days, days inventory outstanding approximately 322 days and days payable outstanding approximately 76 days, implying a cycle of roughly 332 days. The inventory figure overstates true working-capital intensity because reported cost of sales excludes pre-approval production costs already expensed. The genuinely notable number is the 86-day DSO — long for a pharmaceutical business, reflecting medical-benefit reimbursement and specialty-pharmacy payment terms, and a real drag on cash conversion that Merck's scale would compress.
Drivers, inflections and commentary by year
FY2020 — the pivot year. New leadership (Zaccardelli and Hahn, February 2020), a USD 200 million private placement in July, and AIM delisting on 30 October. R&D of USD 44.5 million funded ENHANCE initiation. Net loss USD 65.1 million on nil revenue.
FY2021 — peak clinical burn, offset by the China licence. R&D rose 78% to USD 79.4 million as the bulk of ENHANCE enrolment occurred. The USD 40.0 million Nuance upfront was recognised in full as revenue, cutting the net loss to USD 55.6 million despite higher operating spend. SG&A rose USD 4.1 million, including USD 4.0 million of transaction advisory fees on the Nuance agreement. Cash fell USD 39.6 million to USD 148.4 million.
FY2022 — data year. R&D fell 38% to USD 49.3 million as ENHANCE completed. ENHANCE-2 read out positive in August, ENHANCE-1 in December. SG&A fell to USD 26.6 million, largely on a USD 7.1 million reduction in share-based compensation. Balance sheet rebuilt through a USD 150 million upsized equity raise and a USD 150 million Oxford Finance facility; cash rose to USD 227.8 million. Net loss USD 68.7 million.
FY2023 — pre-commercial build. R&D collapsed 65% to USD 17.2 million with trials complete. SG&A nearly doubled to USD 50.4 million as commercial infrastructure was assembled ahead of the June 2024 PDUFA date. Interest income of USD 12.8 million on a large cash balance materially cushioned the loss, which fell to USD 54.4 million — the lowest in the five-year window. Cash reached USD 271.8 million.
FY2024 — the launch year and the loss peak. Revenue arrived: USD 42.3 million of Ohtuvayre net sales in under five months of selling. But the cost of getting there was severe. SG&A tripled to USD 149.8 million, driven by USD 29.7 million of incremental marketing and commercial activity, USD 26.8 million of people costs as the field force was hired, USD 18.8 million of additional share-based compensation, USD 7.3 million of professional and IT costs, and a USD 15.0 million first-commercial-sale milestone to Ligand. R&D rose to USD 44.6 million on two new Phase 2 starts plus a USD 6.3 million regulatory-approval milestone to Ligand. Below the line, interest expense jumped to USD 23.5 million on the Oaktree/OMERS structures, and a USD 10.3 million tax charge — the first material tax expense in the Company's history — pushed the net loss to USD 173.4 million, the largest ever recorded. Cash nonetheless rose USD 128.0 million to USD 399.8 million on the strength of USD 167.9 million of net debt and RIPSA proceeds plus USD 100 million of Q4 ATM equity.
H1 2025 — the crossover. Product sales of USD 174.2 million in six months exceeded the entire prior-year total by more than four times. Operating income turned positive at USD 2.988 million for the half and USD 13.305 million in Q2 alone. Q2 2025 produced the Company's first quarterly net income: USD 11.921 million. Gross margin on product sales reached 95.4%. The remaining drag was financing cost — USD 17.0 million of interest expense in the half against USD 8.2 million of interest income — and non-cash share-based compensation of USD 72.3 million, which alone exceeded operating income by more than 24 times and is the reason GAAP net income lagged cash generation. Accumulated deficit closed the half at USD 567.1 million.
7. SEGMENTAL AND GEOGRAPHIC REVENUE MAPPING
Revenue by geography: notes and sources
Sources: FY2021, FY2022 and FY2024 results releases; Q2 2025 Form 10-Q. Geographic attribution is derived by the analyst from the disclosed nature of each revenue stream — the Company did not publish a formal geographic segment note, as it had a single segment and, in the commercial period, a single selling territory.
Country-level detail
United States — 100% of product revenue in every commercial period. Ohtuvayre was approved and marketed only in the United States by Verona itself. Within the US, revenue concentration by customer was extreme: five specialty pharmacies accounted for all product sales and all outstanding product accounts receivable. For the three months ended 30 June 2025, the five accounted for 47%, 31%, 20%, 1% and 1% of net product sales respectively; for the six months, 47%, 29%, 18%, 4% and 2%. The top two customers therefore represented 78% of Q2 2025 net product sales — a concentration the Company flagged explicitly as a risk (Q2 2025 Form 10-Q, "Concentration of risk").
Greater China — partnered, non-consolidated. Revenue from this territory was licence and milestone income, not product sales: USD 40.0 million upfront in FY2021, USD 0.458 million of clinical supply sales in FY2022, and USD 5.0 million in Q1 2025 on Nuance Pharma completing last-patient treatment in its Phase 3 trial. Ohtuvayre's Macau approval in February 2025 was the first ex-US approval anywhere.
Europe and United Kingdom — nil. MAAs were submitted in June 2025 (UK) and July 2025 (EU). The EU application was withdrawn on 30 October 2025 post-acquisition. As of April 2026 the MHRA had not approved Ohtuvayre and no NICE appraisal had been initiated.
Fastest-growing and declining regions
Fastest growing: United States. From nil to USD 174.2 million of half-year revenue in four quarters. Under Merck ownership the trajectory continued: USD 178 million in Q4 2025, USD 131 million in Q1 2026 and USD 204 million in Q2 2026.
Declining: none, structurally — but the ex-US pipeline reversed. The EU withdrawal represents the single clearest deterioration in the geographic story. Merck concluded that continuing the EU MAA process was, in the words of the withdrawal letter, not aligned with current business objectives and portfolio strategy. Whatever the commercial logic, the practical effect is that Ohtuvayre's addressable geography narrowed after the acquisition rather than expanding.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Share Count (millions)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Total revenue, net (USD Mn) | 0 | 40.000 | 0.458 | 0 | 42.279 |
Cost of sales (USD Mn) | 0 | 0 | 0.346 | 0 | 2.582 |
Gross profit (USD Mn) | 0 | 40.000 | 0.112 | 0 | 39.697 |
Research and development (USD Mn) | 44.505 | 79.406 | 49.283 | 17.216 | 44.574 |
Selling, general and administrative (USD Mn) | 29.772 | 33.907 | 26.579 | 50.353 | 149.750 |
Total operating expenses excluding cost of sales (USD Mn) | 74.277 | 113.313 | 75.862 | 67.569 | 194.324 |
Operating loss (USD Mn) | -74.277 | -73.313 | -75.750 | -67.569 | -154.627 |
UK research and development tax credit (USD Mn) | 8.267 | 15.630 | 9.634 | 1.104 | 3.600 |
Interest income (USD Mn) | 0.121 | 0.014 | 2.821 | 12.761 | 15.262 |
Interest expense (USD Mn) | -0.035 | -0.340 | -0.521 | -2.057 | -23.542 |
Loss on extinguishment of debt (USD Mn) | 0 | 0 | -0.815 | 0 | -3.653 |
Fair value movement on warrants (USD Mn) | -1.136 | 2.246 | 0 | 0 | 0 |
Foreign exchange gain/(loss) (USD Mn) | 2.060 | 0.176 | -3.817 | 1.866 | -0.169 |
Total other income/(expense), net (USD Mn) | 9.277 | 17.726 | 7.302 | 13.674 | -8.502 |
Loss before income taxes (USD Mn) | -65.000 | -55.587 | -68.448 | -53.895 | -163.129 |
Income tax benefit/(expense) (USD Mn) | -0.146 | 0.018 | -0.253 | -0.474 | -10.289 |
Net loss (USD Mn) | -65.146 | -55.569 | -68.701 | -54.369 | -173.418 |
EBITDA, approximate (USD Mn) | -73.7 | -72.7 | -75.1 | -66.9 | -153.5 |
Weighted average ordinary shares, basic and diluted (millions) | 262.933 | 473.188 | 529.072 | 634.143 | 652.311 |
Loss per ordinary share, basic and diluted (USD) | -0.25 | -0.12 | -0.13 | -0.09 | -0.27 |
Loss per ADS, derived at 8:1 (USD) | -1.98 | -0.94 | -1.04 | -0.69 | -2.13 |
Dividends per share (USD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Gross margin on revenue (%) | 100.0 | 24.5 | 0 | 93.9 |
Operating margin (%) | -183.3 | -16,539.3 | 0 | -365.7 |
Net margin (%) | -138.9 | -14,999.1 | 0 | -410.2 |
R&D as % of total operating expenses | 70.1 | 65.0 | 25.5 | 22.6 |
SG&A as % of total operating expenses | 29.9 | 35.0 | 74.5 | 77.4 |
Balance Sheet
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Cash and cash equivalents (USD Mn) | 187.986 | 148.380 | 227.827 | 271.772 | 399.757 |
Total assets (USD Mn) | 204.206 | 186.587 | 259.468 | 308.124 | 474.242 |
Total liabilities, derived as assets less equity (USD Mn) | 19.352 | 38.582 | 29.002 | 58.841 | 269.683 |
Total shareholders' equity (USD Mn) | 184.854 | 148.005 | 230.466 | 249.283 | 204.559 |
Goodwill (USD Mn) | 0.545 | 0.545 | 0.545 | 0.545 | 0.545 |
Equity interest in Nuance Biotech (USD Mn) | 0 | 15.000 | 15.000 | 15.000 | 15.000 |
Financial Analysis
| Metric | FY2023 | FY2024 | H1 2025 |
|---|---|---|---|
Cash and cash equivalents | 271,772 | 399,757 | 438,016 |
Accounts receivable, net | 0 | 31,496 | 82,858 |
Inventory, current | 0 | 6,249 | 8,612 |
Inventory, long-term | 0 | 1,972 | 5,910 |
Tax incentive receivable | 10,954 | 5,762 | 4,061 |
Total current assets | 289,708 | 453,572 | 548,851 |
Right-of-use assets | 2,847 | 2,048 | 1,574 |
Total assets | 308,124 | 474,242 | 572,871 |
Accounts payable | 3,492 | 11,266 | 3,434 |
Accrued expenses | 3,585 | 16,757 | 43,328 |
Total current liabilities | 8,692 | 42,681 | 51,238 |
Term loan, non-current | 48,374 | 120,341 | 242,434 |
RIPSA liability, current plus non-current | 0 | 106,107 | 0 |
Total liabilities | 58,841 | 269,683 | 294,598 |
Accumulated deficit | 388,433 | 562,401 | 567,101 |
Total shareholders' equity | 249,283 | 204,559 | 278,273 |
Working capital, current assets less current liabilities | 281,016 | 410,891 | 497,613 |
Net cash / (net debt) | 223,398 | 173,309 | 195,582 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Cash and cash equivalents at year end (USD Mn) | 148.380 | 227.827 | 271.772 | 399.757 |
Net change in cash for the year, derived (USD Mn) | -39.606 | 79.447 | 43.945 | 127.985 |
Returns & Leverage Ratios
| Metric | H1 2024 | H1 2025 |
|---|---|---|
Net cash provided by/(used in) operating activities (USD Mn) | -30.712 | 19.000 |
Purchases of furniture and equipment / capex (USD Mn) | -0.045 | -0.535 |
Free cash flow, derived (USD Mn) | -30.757 | 18.465 |
Proceeds from term loans (USD Mn) | 122.500 | 122.500 |
Proceeds from RIPSA (USD Mn) | 100.000 | 0 |
Repurchase of RIPSA (USD Mn) | 0 | -109.921 |
Repayment of 2023 term loans (USD Mn) | -52.256 | 0 |
Proceeds from exercise of share options (USD Mn) | 0.816 | 10.108 |
Net cash provided by financing activities (USD Mn) | 163.709 | 18.400 |
Share-based compensation, non-cash (USD Mn) | 19.852 | 72.291 |
Interest paid (USD Mn) | 2.021 | 16.397 |
Income taxes paid (USD Mn) | 0 | 9.176 |
Returns & Leverage Ratios (%)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Return on equity, end-period basis (%) | -35.2 | -37.5 | -29.8 | -21.8 | -84.8 |
Return on assets, end-period basis (%) | -31.9 | -29.8 | -26.5 | -17.6 | -36.6 |
Cash as % of total assets | 92.1 | 79.5 | 87.8 | 88.2 | 84.3 |
Equity as % of total assets | 90.5 | 79.3 | 88.8 | 80.9 | 43.1 |
Financial Ratios (x) and Key Financials
| Metric | FY2023 | FY2024 | H1 2025 |
|---|---|---|---|
Current ratio (x) | 33.33 | 10.63 | 10.71 |
Debt to equity, all interest-bearing obligations (x) | 0.19 | 1.11 | 0.87 |
Net debt / (net cash) (USD Mn) | -223.398 | -173.309 | -195.582 |
Asset turnover, revenue over end-period assets (x) | 0 | 0.09 | 0.63 |
Interest coverage, EBIT over interest expense (x) | 0 | 0 | 0.18 |
Key Financials
| Region | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
United States, product sales (USD Mn) | 0 | 0 | 0 | 42.261 |
Greater China, licence, milestone and clinical supply (USD Mn) | 40.000 | 0.458 | 0 | 0.018 |
Rest of world (USD Mn) | 0 | 0 | 0 | 0 |
Total (USD Mn) | 40.000 | 0.458 | 0 | 42.279 |
Key Financials (Half-Yearly)
| Region | H1 2024 | H1 2025 |
|---|---|---|
United States, product sales (USD Mn) | 0 | 174.195 |
Greater China, milestone and other (USD Mn) | 0 | 5.199 |
Total (USD Mn) | 0 | 179.394 |
Share Price & Returns
| Date | Event | ADS price (USD) |
|---|---|---|
27 April 2017 | Nasdaq IPO price | 13.50 |
Jan–Mar 2023 | ATM programme — 2,540,173 ADSs for USD 56.9m net; average derived | 22.40 |
30 June 2024 | Aggregate market value of voting and non-voting common equity held by non-affiliates: approximately USD 1.1 billion | — |
Q4 2024 | ATM programme — USD 100m sold at a stated average price | 39.35 |
8 July 2025 | Close on the day before announcement | 86.86 |
9 July 2025 | Intraday, 10:15 a.m. following announcement (up 21%) | 104.79 |
6–7 October 2025 | Final reference price at completion | 106.91 |
Transaction | Consideration per ADS | 107.00 |
Income Statement
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 |
|---|---|---|---|---|
Ohtuvayre net product sales (USD Mn) | 5.600 | 36.637 | 71.300 | 102.939 |
Total net revenue (USD Mn) | 5.600 | 36.655 | 76.256 | 103.138 |
Net income/(loss) (USD Mn) | -43.000 | -33.827 | -16.319 | 11.921 |
Cash and cash equivalents at period end (USD Mn) | 336.000 | 399.757 | 401.400 | 438.016 |
Capital Markets Data
| Metric | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|
Ohtuvayre net sales (USD Mn) | 178 | 131 | 204 |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Transaction value (USD Bn) | 10.0 | Merck and Verona disclosure |
Equity value at USD 107 per ADS (USD Bn) | 9.22 | Derived: 86,192,121 ADS × USD 107 |
EV / trailing twelve-month revenue (x) | 45.1 | Derived: USD 10.0bn / USD 221.65m TTM revenue to Q2 2025 |
EV / annualised Q2 2025 revenue (x) | 24.2 | Derived: USD 10.0bn / (USD 103.138m × 4) |
EV / consensus FY2025 revenue (x) | 24.4 | Derived using the reported analyst consensus of approximately USD 409m |
EV / implied peak sales at a 3x multiple (USD Bn) | 3.0–3.5+ | Jefferies commentary at announcement |
Premium to undisturbed price (%) | 23 | USD 107.00 versus the USD 86.86 close on 8 July 2025 |
Capital Markets
| Metric | Consensus | Actual | Variance |
|---|---|---|---|
Q4 2024 revenue (USD Mn) | 12.94 | 36.66 | +183% |
Q4 2024 EPS per ADS (USD) | Estimate exceeded | -0.05 per ordinary share | Beat |
Q1 2025 revenue (USD Mn) | 41.29 | 76.26 | +85% |
Q2 2025 Ohtuvayre net sales (USD Mn) | 91.80 | 102.94 | +12% |
FY2025 Ohtuvayre net sales (USD Mn) | 402–409 | Not comparable — company acquired mid-year | — |
Catalyst Details
| Catalyst | Expected timing | Why it matters |
|---|---|---|
Q3 2026 Ohtuvayre sales | Merck Q3 2026 results, expected late October 2026 | The cleanest read on underlying demand, since Merck has pre-announced the unwind of Q2 channel timing. A print materially below approximately USD 180m would suggest the Q2 strength was substantially inventory |
Phase 2b fixed-dose combination readout | Not publicly dated post-acquisition | The single largest lifecycle value driver; would create a new nebulised category |
Phase 2 bronchiectasis readout | Not publicly dated post-acquisition | A positive result opens an indication with no approved therapy |
MHRA decision on the UK MAA | Pending since June 2025 | Would restore some ex-US optionality; a further withdrawal would confirm a US-only strategy |
Any resubmission of the EU MAA | Right expressly reserved in the withdrawal letter | Would reverse the most negative post-deal development |
Resolution of the Nuance Pharma buy-back dispute | Unresolved | Determines whether Greater China economics are royalty-based or wholly owned |
CMS and payer policy developments affecting Part B / medical-benefit reimbursement | Continuous | Demonstrated to be the dominant short-term swing factor |
Competitive readouts — tanimilast, tozorakimab, Nucala in COPD | Ongoing | Would erode the mechanistic monopoly |
Any Orange Book patent challenge or paragraph IV certification | Post-June 2028 (four-year NCE window) | The first test of the patent estate |
Capital Markets — Transaction value
| Item | Conflicting values | Resolution |
|---|---|---|
Transaction value | USD 10 billion (Merck, MSD, Verona, all primary releases) versus USD 10.8 billion (Achieve Life Sciences press release, May 2026) | Use USD 10 billion — primary-source consistent. The USD 10.8bn figure appears erroneous or a fully diluted variant |
Employee headcount timing | The North Carolina Biotechnology Center reported "209 full-time employees at the end of 2020"; SEC-derived data places 209 at 31 December 2024 with 79 at 31 December 2023 | Use 209 at 31 December 2024. The 2020 attribution appears to be a reporting error |
Global COPD prevalence | Approximately 384 million (WHO, cited FY2021) versus approximately 392 million (GOLD, cited FY2024) | Use 392 million for current purposes; the difference reflects source and vintage, not a data error |
Net cash at 30 June 2025 | USD 195.582m derived from the balance sheet (cash USD 438.016m less term loan carrying value USD 242.434m) versus USD 193.64m reported by a third-party aggregator using USD 244.37m of debt | Use the balance-sheet-derived USD 195.582m; the aggregator appears to gross up for accrued items |
Executive Leadership
Executive Leadership Team
| Name | Title | Age | Tenure in role | Selected prior roles | Education |
|---|---|---|---|---|---|
David Zaccardelli, Pharm.D. | President, Chief Executive Officer and Executive Director | 60 | Since 1 February 2020 | President and CEO, Dova Pharmaceuticals (Dec 2018 – Nov 2019, acquired by Swedish Orphan Biovitrum for up to USD 915m); Acting CEO, Cempra (2016–2017); board member, Melinta Therapeutics (2017–2020); COO, Chief Manufacturing Officer and EVP Pharmaceutical Development and Operations, United Therapeutics (2004–2016); earlier clinical research roles at Burroughs Wellcome, Glaxo Wellcome and Bausch & Lomb Pharmaceutical | Pharm.D., University of Michigan |
Mark W. Hahn | Chief Financial Officer | 62 | Since February 2020 | CFO, Dova Pharmaceuticals (2018–2019); CFO, Cempra (2010–2017), leading its IPO and follow-on offerings; board member, ALSP Orchid Acquisition Corporation I (2021–2023); began career at Ernst & Young | B.B.A. Accounting and Finance, University of Wisconsin-Milwaukee; CPA (Maryland and North Carolina) |
Kathleen Rickard, M.D. | Chief Medical Officer | 66 | Since February 2019 | CMO, Aerocrine AB and subsequently Circassia (2011–2019); Chief Compliance Officer, Aerocrine (2014–2019); VP Clinical Development and Medical Affairs, GlaxoSmithKline Respiratory Medicines Development Centre, with 15 years in GSK's global respiratory franchise | M.D., Hahnemann University Hospital, Philadelphia |
Andrew Fisher | General Counsel | 55 | Since March 2024 | Founder, Andrew Fisher LLC consulting practice (2019–2024); EVP, Chief Strategy Officer and Deputy General Counsel, United Therapeutics (2001–2018) | Not disclosed in the proxy |
Board of Directors
| Director | Role | Principal outside affiliation as disclosed |
|---|---|---|
David Ebsworth, Ph.D. | Chairperson of the Board (Non-Executive) | Non-Executive Director, Sartorius AG |
David Zaccardelli, Pharm.D. | President, CEO and Executive Director | — |
Christina Ackermann | Non-Executive Director (appointed 2024) | Not disclosed in retrieved excerpts |
Michael Austwick | Non-Executive Director (appointed 1 February 2024) | Over 15 years of respiratory development and commercialisation leadership |
James Brady | Non-Executive Director | Formerly CFO of MedImmune, AstraZeneca's biologics division |
Ken Cunningham, M.D. | Non-Executive Director | Non-Executive Chair, Medherant Ltd |
Lisa Deschamps | Non-Executive Director | CEO, AviadoBIO Ltd |
Martin Edwards, M.D. | Non-Executive Director | Formerly Senior Partner, Novo Holdings A/S |
Mahendra Shah, Ph.D. | Non-Executive Director | Senior Fellow, Vivo Capital LLC |
Vikas Sinha | Non-Executive Director | CFO, ElevateBio, Inc. |
Anders Ullman, M.D., Ph.D. | Non-Executive Director | Head of R&D and Chief Medical Officer, Sobi AB |
Rishi Gupta | Non-Executive Director — resigned effective 31 January 2024 | Partner, OrbiMed Advisors LLC |
Board of Directors (Annual)
| Director | Held at 31 December 2024 | Held at 31 December 2023 | Value at deal price of USD 13.375 per ordinary share (USD) |
|---|---|---|---|
David Zaccardelli | 11,204,752 | 11,766,864 | 149,863,558 |
David Ebsworth | 940,003 | 844,643 | 12,572,540 |
Martin Edwards | 144,800 | 144,800 | 1,936,700 |
Anders Ullman | 334,856 | 334,856 | 4,478,699 |
Vikas Sinha | 74,440 | 74,440 | 995,635 |
Mahendra Shah | 73,080 | 73,080 | 977,445 |
Lisa Deschamps | 70,320 | 70,320 | 940,530 |
Ken Cunningham | 66,584 | 66,584 | 890,561 |
Christina Ackermann | 41,880 | 0 | 560,145 |
James Brady | 0 | 0 | 0 |
Michael Austwick | 0 | 0 | 0 |
Rishi Gupta | 0 | 0 | 0 |
Directors' Remuneration
| Percentage change | 2024 vs 2023 | 2023 vs 2022 | 2022 vs 2021 | 2021 vs 2020 | 2020 vs 2019 |
|---|---|---|---|---|---|
Zaccardelli base salary (%) | 4 | 5 | 3 | 3 | 71 |
Zaccardelli short-term incentive (%) | 9 | -11 | 51 | -20 | 78 |
Zaccardelli taxable benefits (%) | 6 | -53 | 2 | -33 | 10 |
Average employee base salary (%) | 5 | 6 | 10 | 11 | 9 |
Ebsworth base fee (%) | 23 | 0 | 0 | 4 | 4 |
Cunningham base fee (%) | 30 | 0 | 0 | 0 | 0 |
Ullman base fee (%) | 33 | 0 | -9 | 5 | 4 |
Shah base fee (%) | 35 | 0 | — | — | — |
Targets & Commitments
| Initiative | Date | Detail and status |
|---|---|---|
USD 650 million strategic financing | 9 May 2024 | Oaktree Capital and OMERS Life Sciences; non-dilutive; extended cash runway beyond 2026; funded the US launch |
US commercial launch of Ohtuvayre | 6 August 2024 | Exclusive specialty pharmacy network; approximately 120 field staff; speaker education programme with roughly 120 programmes completed by end-2024 |
Phase 2 fixed-dose combination programme | Q3 2024 initiation | Glycopyrrolate dose-ranging completed; Phase 2b planned H2 2025 |
Phase 2 bronchiectasis programme | Q3 2024 initiation | Enrolling at final disclosure; targets an indication with no approved therapies |
GOLD 2025 inclusion | November 2024 | Ohtuvayre added to the GOLD COPD treatment algorithm — a critical guideline-adoption milestone |
Permanent J-code (J7601) | Effective 1 January 2025 | Removed the principal reimbursement friction for a medical-benefit product |
Balance sheet simplification | March 2025 | RIPSA repurchased in full; term loan upsized to USD 450 million; interest rate cut from 11.00% to 9.70%; management stated this "increased the Company's financial flexibility, reduced the cost of capital and simplified the balance sheet" |
Sales force expansion | Announced April 2025 | Approximately 30 additional sales representatives planned for Q3 2025 to deepen the prescriber base |
EU and UK regulatory filings | June–July 2025 | MAAs submitted to MHRA and EMA; the EU application was subsequently withdrawn on 30 October 2025 |
Greater China buy-back | 24 June 2025 | Buy-Back Notice served on Nuance Pharma to reacquire the licence, sublicences and related assets — a decisive strategic reversal from the partnering model, disputed by Nuance and unresolved at completion |
Sale of the Company | 8 July 2025 | Transaction Agreement with Merck at USD 107 per ADS |
Competitive Landscape
Key Competitors
| Competitor | Owner | Product(s) | Class | Delivery | Competitive relationship to Ohtuvayre |
|---|---|---|---|---|---|
Trelegy Ellipta | GSK plc | fluticasone furoate / umeclidinium / vilanterol | Triple ICS/LAMA/LABA | DPI | The dominant COPD brand and Ohtuvayre's principal share-of-wallet competitor; approximately 50% of Ohtuvayre use was on background triple therapy, so the relationship is more additive than substitutive |
Breztri Aerosphere | AstraZeneca plc | budesonide / glycopyrrolate / formoterol | Triple ICS/LAMA/LABA | pMDI | Approved US July 2020, EU December 2020, China December 2019; direct triple-therapy competitor |
Trimbow | Chiesi Farmaceutici | beclometasone / formoterol / glycopyrronium | Triple ICS/LAMA/LABA | pMDI | Approved EU 2017; Phase 3 in the US |
Symbicort | AstraZeneca plc | budesonide / formoterol | ICS/LABA | DPI/pMDI | Legacy dual therapy; large installed base |
Advair, Breo, Anoro | GSK plc | fluticasone/salmeterol; fluticasone furoate/vilanterol; umeclidinium/vilanterol | ICS/LABA and LAMA/LABA | DPI | Legacy franchises; heavily genericised in the case of Advair |
Spiriva | Boehringer Ingelheim GmbH | tiotropium | LAMA | DPI/soft mist | Long-standing monotherapy standard |
Yupelri | Viatris / Theravance Biopharma | revefenacin | LAMA | Nebulised | The most direct nebulised competitor; competes for the same delivery-modality patient |
Brovana | Sunovion / Sumitomo | arformoterol | LABA | Nebulised | Nebulised competitor |
Perforomist | Viatris | formoterol | LABA | Nebulised | Nebulised competitor |
Daliresp | AstraZeneca plc | roflumilast | Oral PDE4 inhibitor | Oral | Mechanistically closest predecessor; constrained by systemic gastrointestinal toxicity — nausea, emesis, diarrhoea, abdominal pain, appetite loss, weight loss — which Ohtuvayre's inhaled delivery avoids |
Dupixent | Sanofi / Regeneron | dupilumab | Anti-IL-4Rα biologic | Injectable | Approved US September 2024 for approximately 300,000 COPD patients with an eosinophilic phenotype; the first injectable biologic in COPD; addresses a narrower population than Ohtuvayre's broad label |
Nucala | GSK plc | mepolizumab | Anti-IL-5 biologic | Injectable | Phase 3 for COPD exacerbation prevention at the time of the FY2024 10-K |
Tozorakimab | AstraZeneca plc | anti-IL-33 | Biologic | Injectable | Phase 3 for COPD exacerbation prevention |
Tanimilast | Chiesi Farmaceutici | inhaled PDE4 inhibitor | Inhaled PDE4 | Inhaler | The closest mechanistic follower — but single-PDE, not dual |
Peer Comparison FY2025
| Metric | Value | Period | Source |
|---|---|---|---|
Verona Pharma trailing twelve-month revenue at acquisition (USD Mn) | 221.65 | Q3 2024 – Q2 2025 | Derived from Verona quarterly filings |
Verona Pharma trailing twelve-month net loss at acquisition (USD Mn) | -81.22 | Q3 2024 – Q2 2025 | Derived from Verona quarterly filings |
Verona Pharma gross margin on product sales (%) | 95.4 | Q2 2025 | Q2 2025 Form 10-Q |
Verona Pharma R&D intensity, R&D over revenue (%) | 15.1 | H1 2025 | Q2 2025 Form 10-Q |
Merck total worldwide sales (USD Bn) | 65.0 | FY2025 | Merck FY2025 results |
Merck Keytruda/Keytruda Qlex sales (USD Bn) | 31.7 | FY2025 | Merck FY2025 results |
Merck Winrevair sales (USD Bn) | 1.4 | FY2025 | Merck FY2025 results |
Johnson & Johnson PAH franchise revenue (USD Bn) | 4.43 | FY2025 | Reported in industry coverage of Merck's Q4 2025 |
Recent Developments
--



